Market Overview

UBS Sees PharMerica As A 'Show-Me' Story, Downgrades To Neutral


UBS’ A.J. Rice downgraded the rating for PharMerica Corporation (NYSE: PMC) from Buy to Neutral, while reducing the price target from $40 to $22. He expects 2016 to be a transitional year for the company.

While announcing its 2016 guidance, management cited a number of headwinds:

  1. Continued bed losses in the first half of the year
  2. Pressure on gross margins from the AMP rule implementation
  3. Pressure on volumes in the core LTC business
  4. Reimbursement headwinds related to Part D contract negotiations

Management also indicated that recently signed new contracts offer PharMerica a more stable trajectory for 2017 and 2018. “While we agree the signing of long-term contracts can provide enhanced visibility on out-year growth, we think PMC could well be a 'show-me' story in 2016,” analyst A.J. Rice wrote.

Estimate Changes

The EPS estimates for 2016, 2017 and 2018 have been reduced from $2.30 to $1.99, from $2.70 to $2.24 and from $3.10 to $2.44, respectively. The company may generate some margin improvement from trimming costs and incremental benefit from the new contracts, Rice added.

Latest Ratings for PMC

Aug 2017DowngradesOutperformNeutral
Aug 2017DowngradesOutperformUnderperform
Jun 2016AssumesBuy

View More Analyst Ratings for PMC
View the Latest Analyst Ratings

Posted-In: A.J. Rice UBSAnalyst Color Downgrades Price Target Analyst Ratings


Related Articles (PMC)

View Comments and Join the Discussion!

Latest Ratings

KSURaymond JamesReiterates188.0
WTRB of A SecuritiesDowngrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at